Shots: Mulpleta is approved based on two randomized, placebo-controlled trials (L-PLUS 1 & 2) involving 312 patients with platelets ≤50 x 109/L randomized 1:1 to receive 3mg once upto 7 […]readmore
Biosimilars
Pharma
Pfizer receives EU approval for Trazimera(Trastuzumab), the First Oncology Biosimilar
Shots: Trazimera is a biosimilar of Herceptin indicated for treatment of HER2 overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma The EC approval is based on the data […]readmore
Shots: Nalpropion buys global commercialization rights of Orexigen’s Contrave a weight loss drug. Nalpropion is an investor group which includes Pernix Contrave has approx. 2.5 Mn prescription since 2014, presently, […]readmore
Shots: AZEDRA radio therapeutic indicated to treat adult and pediatric patients ≥12yrs with iobenguane scan positive Has shown reduction rate in need of blood pressure medication and tumor size in […]readmore
Shots: Results of 2600 patients trial reported significant i.e. ≥50% reduction in migraine days with comparable safety and tolerability to PBO Aimovig works by blocking calcitonin gene-related peptide […]readmore
Shots: Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study Results of Ph2a COMBAT study is expected in […]readmore
Shots: The extension provides a better understanding to clinicians and initial funding discoveries, molecular analyses, design and conduct of samples for new discoveries in cancer Agreement defines that Dana has […]readmore
Shots: U.S. FDA announces recalling of over 2,508 bottles of Metformin hydrochloride with an extended release tablets of 500 mg, packaged in a 500-count bottle Reason for recall is detection […]readmore
Shots: ChemBio will be using its patented DPP® technology platform to test rapid HCV core antigen assay Parallely, FIND is conducting pilot studies in six countries to introduce novel algorithms […]readmore
Shots: Imfinzi has been approved in unresectable PD-L1 expressing LA NSCLC patients treated with platinum-based CRT Approval is based post-hoc subgroup analyses by PD-L1 expression in addition to PFS & OS […]readmore